Product logins

Find logins to all Clarivate products below.


Interventional Oncology Devices | Market Insights | Europe (Supplemental) | 2025

The European interventional oncology device market will see modest growth through 2033, driven by increasing incidence and prevalence rates of cancer, cost-effectiveness of ablation and embolization devices compared to surgery, improved reimbursement, changing guidelines, launch of innovative products, increasing popularity of minimally invasive surgeries, and growing physician acceptance of interventional oncology procedures. However, growth in this market will be hindered by mixed clinical data, increasing-price competition, and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in Europe from 2019 to 2033.

Related Medtech Insights Reports

Report
Biosurgical Agents – Market Insights – Europe
The Europe biosurgical agent market will exhibit modest growth over the forecast period. This expansion will be fueled by a continued preference for biosurgical agents over alternative solutions,…
Report
Interventional Oncology Devices – Market Insights – Latin America
The Latin American interventional oncology device market will see moderate growth through 2034, driven by a large and rapidly expanding patient pool, improving access to treatment, and the entry of…
Report
Trauma Devices – Market Insights – Europe
Although financial constraints among European healthcare facilities and the rise of GPOs that will exert downward pressure on ASPs will limit the European trauma device market, favorable…
Report
Pain Management Devices – Market Insights – United States
The US pain management device market is driven by continuous product innovation aimed at enhancing treatment efficacy and addressing new indications. Favorable clinical evidence and pain management…
Report
Heart Valve Devices – Market Insights – United States
The US heart valve device market continues to be driven by the introduction of novel products and key approvals for new indications of existing products. In particular, recent approvals of…